Platelets and coronary intervention: some practical precautions.
Blankenship
J C
JC
Department of Cardiology, 21-60, Geisinger Medical Center, Danville, PA 17822, USA.
Iliadis
E A
EA
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D003327:Coronary Disease / Q000188:drug therapy*; D016903:Drug Monitoring; D000077542:Eptifibatide; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000627:therapeutic use; D015994:Incidence; D008297:Male; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D011379:Prognosis; D018570:Risk Assessment; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000453:epidemiology; D000077466:Tirofiban; D014443:Tyrosine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D014443:Tyrosine; D000077466:Tirofiban; D000077542:Eptifibatide; D000077284:Abciximab